A recent study published in Diabetologia has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a significant marker for disease progression in individuals at risk of type 1 ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease. Researchers at Utrecht University unveiled the ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

Treatment with inebilizumab was associated with continued improvement in patients with acetylcholine receptor autoantibody-positive (AChR+) generalized myasthenia gravis (gMG), according to 52-week ...

Revolutionizing the Treatment Landscape Autoantibody-driven conditions can severely impact patients’ quality of life, with limited existing options to address the underlying causes. Nipocalimab ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom impact.